Acrux Ltd has released a press release.
Acruxs sixth generic dossier accepted by FDA for review
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Acrux announces commercial agreement with Padagis
- Successful patent litigation outcome
- Appendix 4D, Half Year Accounts as at 31 December 2021
- Acrux and Harris terminate license agreement
- Acruxs fifth generic dossier accepted by FDA for review
Later from Acrux
- Appendix 4E and FY22 Annual Report
- Remaining balance of R&D Tax Incentive Rebate received
- Chairman and CEO address to AGM
- Mutual Termination of Co-Development Agreement
- Launch of prilocaine and lidocaine cream in United States
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux